Professional overview
Zhang Yuntao is an Associate Chief Physician in the Department of Lymphoma and Hematologic Oncology at Peking University Cancer Hospital. Clinical work focuses on screening, diagnosis, differential diagnosis, and management of treatment-related complications for malignant lymphomas and other cancers.
Areas of focus
Background
- 1992Co-authored a study on in vitro and in vivo antitumor effects of doxorubicin conjugated with gastric cancer monoclonal antibody, published in Acta Pharmaceutica Sinica.
- 1997Co-authored a prognostic analysis of 200 cases of non-Hodgkin lymphoma, published in Chinese Journal of Oncology.
- 2000Co-authored a study on clinical features and prognosis of primary nasal non-Hodgkin lymphoma, published in Cancer.
- 2001Co-authored a paper on treatment approaches for nasal-type extranodal natural killer/T-cell lymphoma, published in Chinese Medical Journal.
- 2015Co-authored a study on outcomes of dose-adjusted Berlin-Frankfurt-Munster-90 regimen without radiotherapy in adolescents and adults with T-cell lymphoblastic lymphoma, published in Medical Oncology.
Frequently asked questions
What does Dr. Zhang Yuntao specialize in?
Screening, diagnosis, differential diagnosis, and management of treatment-related complications for highly aggressive lymphoblastic lymphoma and other malignant tumors.
Which hospital and department is Dr. Zhang Yuntao in?
Department of Lymphoma and Hematologic Oncology at Peking University Cancer Hospital
Sources
- Compiled from public information about the doctor's clinical title, department and areas of focus, rewritten by Find China Doctors.
- Medical licence: National Health Commission doctor registry
Dr. Zhang Yuntao has not reviewed this page.
